Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

  • Innoviva Inc INVA has agreed to acquire Entasis Therapeutics Holdings Inc ETTX at $2.20 per share in cash. 
  • Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis.
  • "This acquisition will build upon our overall strategy to acquire differentiated, high-potential assets in attractive, yet often overlooked, disease areas where our capital and capabilities can make a difference," said Pavel Raifeld, Chief Executive Officer of Innoviva. 
  • "We look forward to working with the Entasis team to advance sulbactam-durlobactam (SUL-DUR) and its broader novel antibacterial pipeline to address the urgent and serious threat posed by multidrug-resistant pathogens," Raifeld added.
  • Established in 2015 as a spin-out from AstraZeneca Plc AZN, Entasis' pathogen-targeted approach has produced a robust clinical and pre-clinical pipeline of potential medicines for multidrug-resistant Gram-negative bacteria, including lead asset SUL-DUR. 
  • In the Phase 3 trial, SUL-DUR achieved all primary and secondary endpoints. An FDA marketing application is expected to be submitted in Q3 of 2022.
  • Price Action: ETTX shares are up 21.1% at $2.18 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!